原发性骨质疏松症课件.ppt

* A selective estrogen-receptor modulator such as raloxifene inhibits bone resorption through the same mechanism as do estrogens.28 Raloxifene increases spine bone mineral density slightly and decreases the risk of vertebral fracture by 40 percent in women with osteoporosis, but it has no effect on the risk of nonvertebral fracture.29 The risk of breast cancer is reduced with long-term use of raloxifene, although the drug is not approved for this indication.30 New selective estrogen-receptor modulators are currently in phase 2 and 3 clinical trials. * * * * * * 　Bone mineral density (BMD) wa s mea sured and que stionnaire s were taken for 5593 people aged above 40 years in five administrative area s in China selected by the stratified2multi2step s2cluster sampling method1 Re s ult s 　The total prevalence rate of o steoporo sis wa s 1611 %1 The prevalence rate among male s wa s 1115 % and among female s wa s 1919 % ( P 0101) 1 There were also o steoporo sis prevalence difference s among citie s , age group s , gender group s and area s1 * the prevalences of osteoporosis in women by sekeletal site and age group. The supine lateral spine had the highest prevalence of osteoporosis before the age of 60 years. Detected rates of osteoporosis at the hip region increased rapidly in subjects over 70 years old. * * Osteoporosis is a contributing factor in 1.5 million fractures treated each year. The approximate number of types of fractures related to Osteoporosis are: Approximately 300,000 hip fractures. Approximately 700,000 vertebral fractures. Approximately 250,000 wrist fractures. Approximately 300,000 fractures at other sites. * * increased from 5% (95% CI, 1-9%) in 50- to 59-year olds to 37% (27-46%) among women age 80 years or older. The age-standardized prevalence of vertebral fractures was 5.5% lower than found by similar methods for women in Rochester, MN, U.S.A. Each SD lower spine bone mineral density (BMD) was associated with a 2.4-fold (1.7-3.5) increased